2-<4-Methyl-phenylamino>-aethylbromid | 753391-72-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-<4-Methyl-phenylamino>-aethylbromid
• 英文别名: N-(2-Bromoethyl)-4-methylbenzenamine；N-(2-bromoethyl)-4-methylaniline
• CAS: 753391-72-9
• 化学式: C₉H₁₂BrN
• 分子量: 214.105
• InChiKey: HHOKSFUFYOBLOH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-(3-Chlorformyloxy-phenyl)-carbaminsaeure-isopropylester 、 2-<4-Methyl-phenylamino>-aethylbromid 在 potassium carbonate 作用下， 以 乙酸乙酯 为溶剂， 生成 3-(1-Methyl-aethoxy-carbonyl-amino)-phenyl-N-(2-bromaethyl)-4-methyl-carbanilat
  参考文献：
  名称：

  FR2335496

  摘要：

  公开号：

文献信息

• SULFAMATO HYDROXAMIC ACID METALLOPROTEASE INHIBITOR
  申请人：G.D. SEARLE & CO.

  公开号：EP1157021A1

  公开（公告）日：2001-11-28
• INDAZOLE ACRYLIC ACID AMIDE COMPOUND
  申请人：Yamaguchi Tetsuo

  公开号：US20100256108A1

  公开（公告）日：2010-10-07

  A compound of the formula: wherein ring X is benzene or pyridine; R 1 is substituted alkyl; R 2 is optionally substituted aryl or optionally substituted heterocyclic group; R 3 is hydrogen or alkyl; R 4 is hydrogen, halogen or alkyl; R 5 is hydrogen or alkyl; R 6 and R 7 are the same or different and each hydrogen or halogen, or a pharmaceutically acceptable salt thereof, which is useful as I Kur blocker effective for preventing or treating cardiac arrhythmia such as atrial fibrillation.
• US4271090A
  申请人：——

  公开号：US4271090A

  公开（公告）日：1981-06-02
• US8022059B2
  申请人：——

  公开号：US8022059B2

  公开（公告）日：2011-09-20
• [EN] SULFAMATO HYDROXAMIC ACID METALLOPROTEASE INHIBITOR<br/>[FR] INHIBITEUR DE METALLOPROTEASE A BASE D'ACIDE HYDROXAMIQUE A SULFAMATE
  申请人：SEARLE & CO

  公开号：WO2000046221A1

  公开（公告）日：2000-08-10

  A sulfamato hydroxamic acid compound that inter alia inhibits matrix metalloprotease activity is disclosed as are a process for preparing the same, intermediate compounds useful in those syntheses, and a treatment process that comprises administering a contemplated sulfamato hydroxamic acid compound in a MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity.